###begin article-title 0
###xml 7 10 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
TCRzetadimlymphocytes define populations of circulating effector cells that migrate to inflamed tissues
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 452 455 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 577 583 559 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 605 608 584 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 831 834 807 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1044 1047 1017 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1190 1193 1160 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
The T-cell receptor zeta (TCRzeta) chain is a master sensor and regulator of lymphocyte responses. Loss of TCRzeta expression has been documented in infectious, inflammatory, and malignant diseases, suggesting that it may serve to limit T-cell reactivity and effector responses at sites of tissue damage. These observations prompted us to explore the relationship between TCRzeta expression and effector function in T cells. We report here that TCRzetadim lymphocytes are enriched for antigen-experienced cells refractory to TCR-induced proliferation. Compared to their TCRzetabright counterparts, TCRzetadim cells share characteristics of differentiated effector T cells but use accessory pathways for transducing signals for inflammatory cytokine gene expression and cell contact-dependent pathways to activate monocytes. TCRzetadim T cells accumulate in inflamed tissues in vivo and have intrinsic migratory activity in vitro. Whilst blocking leukocyte trafficking with anti-TNF therapy in vivo is associated with the accumulation of TCRzetadim T cells in peripheral blood, this T-cell subset retains the capacity to migrate in vitro. Taken together, the functional properties of TCRzetadim T cells make them promising cellular targets for the treatment of chronic inflammatory disease.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B1">1</xref></sup>
###xml 415 416 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 415 416 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B2">2</xref></sup>
###xml 785 786 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 786 786 754 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4"/>
###xml 787 788 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 785 788 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B3">3</xref><xref ref-type="bibr" rid="B4"/>&#8211;<xref ref-type="bibr" rid="B5">5</xref></sup>
###xml 1040 1041 1005 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1040 1041 1005 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B6">6</xref></sup>
The acquisition of immune responsiveness is mediated through the assembly, expression, and function of antigen receptors at the cell surface.1 In T lymphocytes, the antigen T-cell receptor (TCR) is a multiple subunit complex comprising clonotypic, disulfide-linked alpha and beta antigen recognition chains devoid of signaling motifs associated with the invariant chain subunits CD3gamma, delta, and ϵ, and TCRzeta.2 These invariant chains assemble in the mature TCR/CD3 complex as noncovalently linked CD3gammaϵ and CD3deltaϵ heterodimers and disulfide-linked TCRzeta-zeta homodimers and transmit signals inside the cell following TCR ligation-induced tyrosine phosphorylation of immune receptor tyrosine-based activation motifs contained within their extended intracytoplasmic tails.3-5 These phosphotyrosine motifs form docking sites for Syk family tyrosine kinases, such as zeta-associated protein of 70 kDa (ZAP-70), which in turn couple the antigen receptor complex to transmembrane adaptor proteins and downstream signaling pathways.6
###end p 4
###begin p 5
###xml 166 167 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 175 176 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 419 420 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 451 452 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 451 452 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B7">7</xref></sup>
###xml 662 663 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 664 665 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 662 665 612 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></sup>
###xml 961 963 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 964 966 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 961 966 900 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref></sup>
The TCRzeta subunit differs in its genetic organization, chromosomal localization, and domain structure from the CD3gamma, delta, and ϵ invariant chains. Thus, in CD4+ and CD8+ T cells the 16-kDa TCRzeta chain subserves a unique role in TCR/CD3 complex assembly by associating with newly synthesized hexameric alphabetagammaϵdeltaϵ complexes resulting in the transport and expression of mature alphabetagammaϵdeltaϵzeta2 complexes to the cell surface.7 Furthermore, metabolic labeling and pulse chase experiments have demonstrated that de novo synthesis of TCRzeta is rate-limiting, thereby regulating the amount of TCR/CD3 complex expressed at the cell surface.8,9 In NK cells, the TCRzeta chain may form homodimers or heterodimers with the FcϵR common gamma chain signaling subunit, which in turn may form signaling complexes with several activating receptors, including NK cell protein 46 (NKp46), NKp30, and the low-affinity IgG receptor FcgammaRIII (CD16).10,11 In light of these crucial functions the TCRzeta chain could be viewed as a master regulator and sensor of innate as well as adaptive immune responses. It follows from this that aberrations in its expression or function should have profound effects on immune function.
###end p 5
###begin p 6
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B12">12</xref></sup>
###xml 452 454 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 452 454 449 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B13">13</xref></sup>
###xml 746 748 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 749 751 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 746 751 740 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref></sup>
###xml 1063 1065 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1066 1068 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1063 1068 1054 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref></sup>
###xml 265 268 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The events leading to the down-regulation of TCR/CD3 complex expression on serial ligation by peptide/MHC complexes are well documented.12 Less well understood are the molecular mechanisms for the sustained down-regulation of TCRzeta observed in chronic bacterial, HIV, and mycobacterial infections, autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, and in solid tumor and hematologic malignancies (reviewed by Baniyash13). That this phenomenon is associated with so many diverse pathologies has raised the possibility that down-regulation of TCRzeta may serve to attenuate T-cell activation at sites of tissue damage, thereby limiting the effects of unbridled T-cell reactivity and pathologic effector responses.14,15 Whilst this model is entirely consistent with a central role for antigen in driving autoimmune inflammatory activity, it implies that chronically activated T cells rendered hyporesponsive to TCR engagement through loss of TCRzeta expression should play a less prominent role in the established phase of disease.13,14
###end p 6
###begin p 7
###xml 110 113 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
To gain further insight into the immunobiology of T cells expressing low levels of TCRzeta (hereafter, TCRzetadim), we explored the relationship between loss of TCRzeta expression and T-cell function. Our results shed light on the nature of persistent effector responses of T cells that become refractory to antigenic restimulation during the evolution of immune responses. They also have implications for cell-based therapies aimed at achieving long-term remission in patients with chronic inflammatory disease.
###end p 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients, materials, and methods
###end title 8
###begin title 9
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Healthy donors and patients
###end title 9
###begin p 10
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 591 593 591 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B16">16</xref></sup>
###xml 1210 1212 1210 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1210 1212 1210 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 182 185 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 289 292 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 439 447 <span type="species:ncbi:9606">Patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
###xml 936 944 <span type="species:ncbi:9606">patients</span>
###xml 1286 1294 <span type="species:ncbi:9606">patients</span>
Laboratory staff members, aged 22 to 45 years of age, were enrolled as healthy donors. All patients were recruited from the Hammersmith Hospitals NHS Trust (London, United Kingdom). CMV reactive lymphocytes were obtained from HLA-B*0702+ patients with chronic myeloid leukemia selected by CMV seropositivity. Single donor plateletpheresis residues were obtained from the North London Blood Transfusion Service (Colindale, United Kingdom). Patients with severe, active seropositive rheumatoid arthritis (RA) meeting the American College of Rheumatology revised classification criteria for RA,16 and requiring anti-TNF therapy, were recruited to the study. Prior to anti-TNF therapy, all patients were treated with nonsteroidal anti-inflammatory drugs in addition to methotrexate and sulfasalazine, with or without hydroxychloroquine and low-dose prednisolone. Peripheral blood (PB) and synovial fluid (SF) lymphocytes were obtained from patients with RA, psoriatic arthritis, or reactive arthritis who attended the clinic with a flare of disease requiring therapeutic arthrocentesis. Synovial mononuclear cell suspensions were prepared from RA synovial tissue obtained at joint replacement surgery as described.17 Written, informed consent was obtained from all participating donors and patients in accordance with the Declaration of Helsinki, and all protocols were approved by the Riverside Research Ethics Committee, Hammersmith Hospitals NHS Trust.
###end p 10
###begin title 11
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human lymphocytes
###end title 11
###begin p 12
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 498 500 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 630 632 630 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 715 716 715 716 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 467 471 <span type="species:ncbi:9913">calf</span>
PB lymphocytes (PBLs) from heparinized peripheral venous blood (or mononuclear cells from SF) were obtained by Ficoll-Hypaque density gradient centrifugation (specific density 1.077 g/mL; Nycomed Pharma, Oslo, Norway) and used immediately for flow cytometric analysis. Where relevant, additional aliquots were prepared and frozen until required. PB monocytes and T cells were purified by elutriation (JE6; Beckman Coulter, Fullerton, CA) in 1% heat-inactivated fetal calf serum (FCS), as described,17 and purity assessed by flow cytometry. Single-cell suspensions of synovial membrane mononuclear cells were prepared as described.17 Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM l-glutamine, 100 U/mL penicillin/streptomycin, 50 muM 2-ME, 1 mM sodium pyruvate, and 25 mM HEPES (complete medium).
###end p 12
###begin title 13
Antibodies and recombinant cytokines
###end title 13
###begin p 14
###xml 264 269 <span type="species:ncbi:10090">mouse</span>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
###xml 457 462 <span type="species:ncbi:10090">mouse</span>
###xml 872 877 <span type="species:ncbi:9606">Human</span>
The following antibodies were purchased from BD Biosciences PharMingen (San Diego, CA): anti-CD8-APC, anti-CD28-FITC, anti-CD45RA-APC, anti-TNFalpha-FITC, anti-IFNgamma-FITC, and anti-IL-10-APC. Anti-CD45RO-FITC was obtained from Serotec (Oxford, United Kingdom), mouse IgG1-FITC and anti-CD3-FITC from Sigma (St Louis, MO), mouse IgG1-PE and anti-TCRzeta-PE (TIA2, which recognizes a cytoplasmic domain epitope) from Immunotech (Coulter, Hialeah, FL), and mouse IgG-PerCP, anti-CD3-PerCP, anti-CD4-PerCP, anti-CD8-PerCP, anti-CD16-FITC, and anti-CD56-FITC from Becton Dickinson (San Jose, CA). Anti-TCRzeta-FITC (clone 6B10.2, which recognizes a transmembrane epitope of TCRzeta) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-CD3ϵ antibody used for stimulation (clone OKT3) was obtained from the American Type Culture Collection (Rockville, MD). Human recombinant TNF-alpha and IL-2 were generous gifts of Prof W. Stec (Centre of Molecular Studies, Lodz, Poland) and Dr P. Lomedico (Hoffman-La Roche, Nutley, NJ), respectively. All other cytokines were purchased from PeproTech EC (London, United Kingdom) or R&D Systems (Wiesbaden, Germany).
###end p 14
###begin title 15
Flow cytometry
###end title 15
###begin p 16
###xml 322 324 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 322 324 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B18">18</xref></sup>
Cells were stained by standard methods and analyzed using an LSR BD FACScan analyzer and CellQuest software (Becton Dickinson). For analysis of TCRzeta and intracellular cytokine expression, cells were fixed with 2% formaldehyde and permeabilized in buffer containing 10 mug/mL saponin, according to established protocols.18 The efficiency of permeabilization was determined by uptake of trypan blue (always > 99%).
###end p 16
###begin title 17
T-cell stimulation and effector responses
###end title 17
###begin p 18
###xml 911 913 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 911 913 898 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 1509 1512 1487 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1924 1930 1895 1901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1941 1944 1909 1912 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 2097 2099 2065 2067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 2097 2099 2065 2067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 2558 2560 2518 2520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 2558 2560 2518 2520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B19">19</xref></sup>
###xml 2589 2595 2546 2552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 2606 2609 2560 2563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 416 419 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 469 472 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1549 1564 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 2412 2417 <span type="species:ncbi:9606">human</span>
For proliferation, unfractionated PBLs were labeled with 5 muM CFSE (Molecular Probes, Eugene, OR) prior to stimulation in complete medium with plate bound OKT3 (2 mug/mL) with or without soluble anti-CD28 (2 mug/mL). Cells were harvested at the indicated times, stained with specific antibodies to TCRzeta (TIA2-PE), together with anti-CD3, anti-CD4, or anti-CD8 conjugated to PerCP and analyzed by flow cytometry. CMV-reactive PBLs were stimulated with specific pp65 CMV peptide (amino acid sequence: TPRVTGGGAM, from Proimmune, Oxford, United Kingdom) in the presence of 50 U/mL IL-2 and 10 ng/mL IL-7 for up to 8 days prior to staining with anti-TCRzeta (6B10.2-FITC), HLA-B7-tetramer-PE (Proimmune), and anti-CD8-APC and analysis by flow cytometry. Cytokine-activated T cells were generated from elutriated T cells over 8 days using IL-2 (25 ng/mL), TNF-alpha (25 ng/mL), and IL-6 (100 ng/mL) as described.17 Cytokine expression was determined by staining fixed and permeabilized PBL with directly conjugated anticytokine antibodies (all from BD Biosciences PharMingen), after stimulation for 6 hours at 37degreesC with 20 ng/mL phorbol myristate acetate (PMA) and 200 ng/mL ionomycin (both from Sigma). Golgistop (containing monensin, from BD Biosciences PharMingen) was added for the last hour of stimulation. Specificity of staining was confirmed using isotype-specific control antibodies and by ligand-blocking experiments using the corresponding recombinant cytokine. For CD28 stimulation of TCRzetadim cells, T cells were cocultured with Chinese hamster ovary (CHO) cells transfected with CD80 or CD86 (generously provided by Dr D. Sansom, University of Birmingham, Birmingham, United Kingdom) for 24 hours, and supernatants harvested and assayed for IFN-gamma or IL-10 expression by enzyme-linked immunoadsorbent assay (ELISA; BD Biosciences PharMingen). Cell contact-dependent activation of monocytes by TCRzetabright or TCRzetadim T cells fixed in PBS containing 0.05% glutaraldehyde and neutralized with an equal volume of buffer containing 0.2 M glycine was performed as described.17 Stimulation of monocytes with LPS (10 ng/mL) in the absence of T cells was used as a positive control. Culture supernatants were harvested after 24 hours and assayed for TNF-alpha levels by ELISA (BD PharMingen). Transendothelial migration of PBLs or elutriated T cells 24 hours after plating over monolayers of human umbilical vein endothelial cells (HUVECs) previously stimulated with 10 ng/mL TNF-alpha for 48 hours was performed essentially as described.19 Numbers of migrating TCRzetabright or TCRzetadim T cells were determined by flow cytometry.
###end p 18
###begin title 19
Assessment of clinical response
###end title 19
###begin p 20
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 494 496 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B20">20</xref></sup>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 703 705 703 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B21">21</xref></sup>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
Patients with active RA requiring anti-TNF treatment as part of their standard care were identified according to national guidelines. All patients were treated with intravenous infusions of infliximab (3 mg/kg) at week 0, 2, 6, and then 8 weekly thereafter, while continuing existing disease-modifying drug therapy. At baseline and at the indicated times disease activity and response to therapy were determined using the disease activity score (DAS), which includes the 28 joint count (DAS28).20 At baseline, all patients had DAS28 scores of more than 5.1. Good, moderate, and poor responses were defined according to European League Against Rheumatism (EULAR) DAS response criteria at 14 and 30 weeks.21 PBLs were obtained at the indicated times after starting therapy and frozen prior to analysis.
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 40 46 37 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 58 61 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 155 156 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Differences in phenotype between TCRzetabright and TCRzetadim subsets were determined by pair-wise analyses using the Wilcoxon signed rank test or Student t test, according to sample distribution. Correlations between changes in TCRzeta expression and disease activity were determined by linear regression analysis. The limit for statistical significance was set at .05.
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 243 245 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 243 245 237 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B22">22</xref></sup>
###xml 819 820 801 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 827 828 806 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 839 840 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 847 848 823 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 943 951 916 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1052 1058 1019 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1117 1129 1081 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">intermediate</sup>
###xml 1140 1143 1101 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1248 1256 1209 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1412 1413 1373 1374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1420 1421 1378 1379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1472 1473 1427 1428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1482 1483 1437 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1504 1505 1459 1460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1509 1515 1464 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1556 1557 1508 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1574 1575 1526 1527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1579 1580 1531 1532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1607 1613 1556 1562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1783 1785 1729 1731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1783 1785 1729 1731 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 322 327 <span type="species:ncbi:10090">mouse</span>
To study TCRzeta expression at the single-cell level in mixed populations of PBLs from healthy donors we adapted quantitative flow cytometric assays first developed to study deficient zeta-chain expression in T cells from patients with cancer.22 The TCRzeta chain has a short 9 amino acid extracellular domain, so we used mouse monoclonal antibodies (clones TIA-2 or 6B10) that detect cytoplasmic domain epitopes of the zeta chain in T cells after fixing and permeabilization. Both antibodies recognize phosphorylated as well as unphosphorylated forms of the TCRzeta chain, implying that any loss of signal is not due to activation-induced phosphorylation of the zeta-chain polypeptide (data not shown). As expected, staining of PBLs from healthy donors defined distinct lymphocyte subsets, including populations of CD3+TCRzeta+ cells, CD3-TCRzeta+ cells, and a double-negative population of monocytes and B cells that do not express TCRzeta (Figure 1A and data not shown). We documented a relationship between TCRzeta and CD3ϵ expression, with TCRzetabright T cells expressing the highest levels of CD3ϵ, and TCRzetaintermediate or TCRzetadim cells expressing levels of surface CD3ϵ that for some donors were at least an order of magnitude lower (Figure 1A). This relationship varied considerably between donors but was not related to cell viability based on annexin-V staining (data not shown). Analysis of CD3-TCRzeta+ cells confirmed expression of TCRzeta in both CD56+ and CD16+ NK cell subsets; CD3-CD56bright cells were found to be uniformly TCRzeta-, whereas the CD3-CD16+ NK cell subset was TCRzetabright (data not shown; Nicola Dalbeth and Margaret Callan, unpublished data, May 2005). This would be consistent with the physical association between CD16 and the zeta chain.10
###end p 24
###begin p 25
###xml 0 46 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCR&#950; expression in PBLs from healthy donors</bold>
###xml 293 299 278 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 311 314 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 385 386 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 396 397 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 427 433 406 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 445 448 421 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
TCRzeta expression in PBLs from healthy donors. (A) PBLs were analyzed for expression of TCRzeta and CD3 by flow cytometry. Four donors illustrating the heterogeneity of TCRzeta expression are shown. (B) PBLs were stained for TCRzeta and CD3 expression. CD45RA and CD45RO expression on TCRzetabright and TCRzetadim subsets were then determined by flow cytometry. (C) The percent CD45RA+ or CD45RO+ cells residing within TCRzetabright and TCRzetadim subsets were analyzed for 10 or 12 healthy donors, respectively. Horizontal lines represent mean values.
###end p 25
###begin p 26
###xml 455 461 446 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 473 476 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 550 558 538 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 594 595 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 618 624 603 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 651 652 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 688 691 670 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 813 821 795 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 858 864 837 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 930 933 906 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1064 1067 1037 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1104 1110 1074 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
The relationship between antigen engagement and reduced levels of TCRzeta reported previously suggested that TCRzeta expression should discriminate between subsets of naive and memory T-cell subsets defined by conventional cell surface markers. To this end, we stained healthy donor PBLs with antibodies specific for CD45RA or CD45RO to define subsets of naive and memory T cells, respectively, and then compared the expression of these markers on TCRzetabright and TCRzetadim cell subsets. Histogram plots from a representative experiment, shown in Figure 1B, demonstrated enrichment of CD45RA+ T cells in the TCRzetabright population and many CD45RO+ T cells residing within the TCRzetadim subset. Nevertheless, there was considerable overlap between subsets, findings supported by analysis of multiple donors (Figure 1C). Indeed, as many as 40% of TCRzetabright T cells expressed CD45RO, whereas a similar proportion of TCRzetadim T cells expressed CD45RA. More extensive phenotyping failed to demonstrate uniform loss of CD62L or CCR7 expression on all TCRzetadim T cells when compared to the TCRzetabright subset, indicating that low expression of TCRzeta does not define differentiating effector memory T cells per se, but rather analysis of TCRzeta expression might provide additional functional information besides that provided by conventional cell surface phenotyping.
###end p 26
###begin p 27
###xml 232 233 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 241 242 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 629 635 620 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 637 645 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 692 704 680 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">intermediate</sup>
###xml 716 719 701 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 837 840 819 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 844 845 826 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 853 854 835 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1324 1325 1303 1304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1332 1333 1311 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To examine the functional consequences of TCRzeta expression on TCR responsiveness, we stained fresh PBLs from healthy donors with carboxy-fluorescein diacetate succinimidyl ester (CFSE) and tracked the proliferative capacity of CD4+ and CD8+ T-cell subsets in response to stimulation with OKT3, or OKT3 and anti-CD28 in combination. At the indicated times cells were harvested, stained for TCRzeta expression, and analyzed by CFSE dye dilution. Although little proliferation was detected within the first few days of TCR stimulation, dividing T cells could be detected at subsequent time points, and these were uniformly TCRzetabright (Figure 2A arrows). In contrast, the majority of TCRzetaintermediate and TCRzetadim T cells failed to proliferate throughout the period of stimulation. Note that populations of nonproliferating TCRzetadim CD4+ and CD8+ T cells, representing less than 10% of the total, were observed at day 4 but not at subsequent time points. The reasons for this are unknown, although it is conceivable that these T cells undergo programmed cell death after nonproductive TCR engagement. By day 6, expression of TCRzeta in proliferating cells declined progressively with each cycle of cell division. Although this result was predicted, the extent to which proliferation was restricted to a subset of CD4+ or CD8+ T cells expressing high levels of TCRzeta was unexpected. These findings could not be explained by suboptimal levels of TCR stimulation, because higher concentrations of OKT3 and anti-CD28 antibodies induced similar patterns of proliferation with respect to TCRzeta expression.
###end p 27
###begin p 28
###xml 11 14 8 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 0 70 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The TCR&#950;<sup>dim</sup> cell subset is enriched for antigen experienced T cells</bold>
###xml 333 339 324 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 400 401 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 562 563 553 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 702 703 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 744 750 729 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 762 765 744 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 402 405 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 456 459 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The TCRzetadim cell subset is enriched for antigen experienced T cells. (A) Healthy donor PBLs were stained with CFSE prior to stimulation with OKT3. At the indicated times, cells were harvested, stained for TCRzeta together with CD3, CD4, or CD8, and dilution of CFSE fluorescence determined by flow cytometry. Proliferating TCRzetabright cells are indicated (arrows). (B) Fresh PBLs from HLA-B*0702+ CMV-reactive donors were stimulated in vitro with p65 CMV peptide, IL-2, and IL-7. Eight days later, cells were stained for the presence of peptide-reactive CD8+ T cells using fluorescent HLA-B7/p65 MHC-peptide tetramers and anti-CD8. (C) Cells were stained for TCRzeta expression and the percent CD8+ tetramer-positive T cells within TCRzetabright and TCRzetadim subsets determined. The percent tetramer-positive cells is indicated. Data are representative of multiple experiments.
###end p 28
###begin p 29
###xml 112 115 109 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 190 191 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 288 289 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 513 521 510 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 545 551 539 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 563 566 554 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 637 638 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 672 675 660 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 747 753 732 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 798 801 780 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 809 817 791 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 934 942 916 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1185 1188 1161 1164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 192 195 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 244 247 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
It followed from this that after TCR stimulation in vitro, antigen-reactive T cells should reside in the TCRzetadim compartment. To test this directly, we analyzed fresh PBLs from HLA-B*0702+ CMV-reactive donors after stimulation with specific CMV peptide and tracked antigen-specific CD8+ T cells with fluorescent HLA-B7/p65 MHC-peptide tetramers. In a representative experiment, the proportion of tetramer-positive T cells increased from less than 3% prior to stimulation to almost 10% after 8 days of culture (Figure 2B). By gating on TCRzetabright and TCRzetadim T-cell subsets, we confirmed that the majority of peptide-specific CD8+ T cells reside within the TCRzetadim population after 8 days of stimulation (1.27% tetramer-positive TCRzetabright cells versus 26.4% tetramer-positive TCRzetadim cells, Figure 2C); note the downward shift in tetramer staining consequent on down-regulation of the TCR complex after stimulation (Figure 2B-C right panels). Together these experiments demonstrated that TCRzeta staining can be used to identify populations of tetramer-positive T cells that have undergone productive engagement with specific antigen and suggest that circulating zetadim cells represent polyclonal populations of antigen experienced lymphocytes in vivo.
###end p 29
###begin p 30
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 270 272 270 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B23">23</xref></sup>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 460 462 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B24">24</xref></sup>
###xml 500 503 497 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 621 627 615 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1206 1214 1194 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1275 1283 1263 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1309 1312 1294 1297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1426 1432 1400 1406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1465 1473 1439 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1571 1577 1542 1548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1586 1594 1557 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1676 1679 1644 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
A characteristic feature of effector T cells is their capacity to produce cytokines. Current paradigms of T-cell differentiation suggest that T cells undergo a complex series of epigenetic events to acquire stable transcriptional competence for cytokine gene expression.23 These events depend on signals integrated from both the antigen T-cell receptor and cytokine receptors that induce the expression and activation of lineage-specific transcription factors.24 We therefore explored whether TCRzetadim T cells that had already engaged antigen in vivo were competent for cytokine gene expression when compared to TCRzetabright cells from the same donor. To test this, fresh PBLs were stimulated in vitro for 6 hours with phorbol ester and calcium ionophore. This stimulus, in contrast to anti-TCR antibodies, allowed us to assess competence for cytokine gene expression by activating T cells through pathways independent of TCRzeta expression. Monensin was added to cultures for the last hour of stimulation prior to harvesting and staining using specific antibodies for CD3ϵ and TCRzeta in combination with the indicated anticytokine antibody. Representative histogram plots are shown for each cytokine (Figure 3 left panel), alongside data derived from 12 healthy donors (Figure 3 right panel). The TCRzetadim subset (shaded histograms) was enriched for cells expressing TNF-alpha and IFN-gamma when compared to the TCRzetabright population from the same donor (Figure 3A-B). By contrast, the dominant IL-10-producing cell subset was found to reside within the TCRzetabright subset (Figure 3C), indicating that cytokine expression in general was not confined to the TCRzetadim subset. A similar trend was seen for IL-4, but levels of expression were too low for a meaningful statistical analysis.
###end p 30
###begin p 31
###xml 7 10 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 0 69 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCR&#950;<sup>dim</sup> cells are enriched for cytokine-producing effector T cells</bold>
###xml 316 322 299 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 333 336 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
TCRzetadim cells are enriched for cytokine-producing effector T cells. Fresh PBLs were stimulated with PMA and ionomycin for 6 hours prior to staining for CD3, TCRzeta, and intracellular expression of (A) TNF-alpha, (B) IFN-gamma, and (C) IL-10. Data are expressed as percent cytokine-expressing cells within TCRzetabright or TCRzetadim subsets for 12 healthy donors. Horizontal lines represent mean values.
###end p 31
###begin p 32
###xml 65 68 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 258 266 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 293 296 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 455 458 446 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 595 597 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 595 597 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B25">25</xref></sup>
###xml 756 758 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 759 761 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 756 761 736 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B26">26</xref></sup>
###xml 847 850 824 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 902 910 879 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 952 955 926 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1297 1305 1263 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1391 1394 1350 1353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 580 586 <span type="species:ncbi:10090">murine</span>
The results described thus far indicated that circulating TCRzetadim T cells were enriched for cells that had previously engaged antigen and that were primed for cytokine production. However, the proliferative responses of T cells to TCR engagement shown in Figure 2 indicated that the TCRzetadim subset was refractory to membrane proximal TCR signals. To define alternative signaling pathways of effector function, we prepared bulk populations of TCRzetadim T cells by stimulating elutriated T cells with inflammatory cytokines such as TNF-alpha, which down-regulates TCRzeta in murine T cells,25 using a combination of IL-2, IL-6, and TNF-alpha sufficient to support T-cell differentiation in vitro in the absence of specific antigen and accessory cells.22,26 After 7 days of cytokine stimulation a significant proportion of T cells were TCRzetadim (67.3% compared to 12.2% for unstimulated T cells; Figure 4A). We then tested the capacity of TCRzetadim T cells to produce IFN-gamma or IL-10 either in the absence of stimulation or following costimulation by CHO cell transfectants expressing CD80 or CD86; CHO cells expressing empty vector were used as a negative control. In the absence of CHO cells, stimulation with the cytokine cocktail alone was sufficient to induce IFN-gamma production (Figure 4B). Whilst costimulation with CHO/vector cells reduced IFN-gamma production by TCRzetadim T cells, stimulation with CHO cells expressing either CD80 or CD86 was equally efficient in augmenting IFN-gamma production. Neither cytokine nor costimulatory signals were sufficient to induce T-cell IL-10 production.
###end p 32
###begin p 33
###xml 48 51 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 0 59 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Antigen-independent effector function of TCR&#950;<sup>dim</sup> T cells</bold>
###xml 72 75 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 321 324 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 517 523 494 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 545 548 519 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
Antigen-independent effector function of TCRzetadim T cells. (A) TCRzetadim T cells were generated from purified T cells following stimulation for 7 days with IL-2, IL-6, and TNF-alpha in the absence of antigen or antigen-presenting cells. TCRzeta expression is shown compared to that of unstimulated T cells. (B) TCRzetadim T cells were cocultured with CHO cells expressing empty vector, CD80, or CD86 for 24 hours. Supernatants were harvested and IFN-gamma and IL-10 levels determined by ELISA. (C) Resting (TCRzetabright) or activated TCRzetadim T cells were fixed prior to coculture at the indicated ratios with purified monocytes. Supernatants were harvested 24 hours later and TNF-alpha levels determined by ELISA. Supernatants derived from cultures of monocytes or T cells alone or LPS-stimulated monocytes were used as negative and positive controls, respectively. Data are representative of multiple experiments, and represent mean cytokine levels +/- SD in panels B and C.
###end p 33
###begin p 34
###xml 23 26 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 81 87 75 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 98 101 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 376 384 355 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 435 436 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 497 505 469 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 547 550 516 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 850 853 808 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1073 1076 1028 1031 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
To test whether TCRzetadim T cells could reciprocally activate monocytes, TCRzetabright or TCRzetadim T cells were fixed prior to incubation with elutriated monocytes and supernatants harvested 24 hours later and assayed for monocyte-derived TNF-alpha production. Monocytes or T cells alone produced little or no TNF-alpha, whereas LPS stimulation induced abundant TNF-alpha (Figure 4C right panel). Although coculture of fixed TCRzeta+ cells with monocytes failed to elicit TNF-alpha production (Figure 4C left panel), cytokine-stimulated TCRzetadim T cells induced monocytes to produce TNF-alpha in a dose-dependent fashion when T cell-monocyte ratios were increased from 3:1 to 7:1. TNF-alpha production was attenuated when T-cell-monocyte contact was blocked with a Transwell insert (data not shown). These data demonstrated that although TCRzetadim cells are relatively refractory to TCR-induced proliferation, they are by no means senescent or inert, being capable of inflammatory cytokine expression in response to cytokine receptor or costimulatory signals. TCRzetadim cells are also potent activators of monocytes through cell contact-dependent pathways.
###end p 34
###begin p 35
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 417 418 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 425 426 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 507 515 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 554 555 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 562 563 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 679 682 658 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 752 760 731 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 816 819 792 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 876 877 852 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1030 1033 1003 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1085 1093 1058 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1119 1122 1089 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1407 1409 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1410 1412 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1407 1412 1377 1382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref></sup>
###xml 1435 1438 1402 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1608 1611 1570 1573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1854 1855 1816 1817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1862 1865 1821 1824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1887 1895 1846 1854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1934 1935 1893 1894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1947 1948 1906 1907 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2116 2117 2075 2076 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2127 2128 2086 2087 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
###xml 867 874 <span type="species:ncbi:9606">patient</span>
###xml 1451 1459 <span type="species:ncbi:9606">patients</span>
This effector phenotype, being reminiscent of RA synovial T cells,17 prompted us to compare expression of TCRzeta in paired PB and SF T cells from patients with an acute flare of inflammatory arthritis who attended a clinic. TCRzeta expression profiles were notable in several respects. First, a significant proportion of SF T cells had negligible levels of TCRzeta expression, equivalent to that detected in the CD3ϵ-TCRzeta- double-negative cell population, and yet surface expression of CD3ϵ was spared (Figure 5A). Second, although the numbers of CD3-TCRzeta+ NK cells were lower in SF than in PB, expression of TCRzeta was also reduced. Furthermore, lower numbers of TCRzetadim T cells were detected in PB of patients with an acute disease flare (Figure 5B). This was associated with accumulation of the TCRzetadim subset in SF when compared to PB from the same patient (P < .03), suggesting selective migration of these effector cells to inflamed joints and their exit from the circulating pool; increased numbers of TCRzetadim T cells in RA synovial tissue (ST) was consistent (Figure 5B). If circulating TCRzetadim T cells represented populations of antigen-experienced effector cells captured prior to their migration to inflamed joints, then blocking cell migration should lead to accumulation of this subset in blood. We took advantage of the fact that TNF blockade inhibits leukocyte trafficking27,28 by tracking PB TCRzetadim cells in 17 patients with chronic, active RA (DAS28 >/= 5.1) before and after treatment with anti-TNF. We documented considerable variability in expression of PB TCRzetadim T-cell numbers following anti-TNF therapy. However, when data were stratified according to validated EULAR clinical response criteria we found that at 30 weeks the best clinical outcomes were associated with an accumulation in the percent CD3+TCRzetadim T cells at 14 weeks (Figure 5C); this relationship held true for CD4+ but not CD8+ T cells, whereas no such association was found between clinical response to anti-TNF and other cellular parameters, such as total lymphocyte counts, or the percent CD3+ or CD45RO+ T cells (data not shown).
###end p 35
###begin p 36
###xml 7 10 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 0 131 0 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCR&#950;<sup>dim</sup> T cells are enriched at sites of inflammation and accumulate in PB after treatment with anti-TNF in a subset of patients</bold>
###xml 571 572 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 579 582 567 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 631 632 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 639 642 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 210 217 <span type="species:ncbi:9606">patient</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 698 706 <span type="species:ncbi:9606">patients</span>
TCRzetadim T cells are enriched at sites of inflammation and accumulate in PB after treatment with anti-TNF in a subset of patients. (A) A dot plot of TCRzeta versus CD3ϵ expression in PB and SF T cells from a patient with RA, as determined by flow cytometry. (B) Paired PB and SF mononuclear cells from patients with active inflammatory synovitis were stained for TCRzeta and analyzed by flow cytometry. Mononuclear cell suspensions were prepared from synovial tissue (ST) specimens obtained from patients with RA at joint arthroplasty. Data are expressed as percent CD3+TCRzetadim T cells in each compartment. (C) The percent CD3+TCRzetadim cells was determined by flow cytometry in PBLs from 17 patients with RA at baseline and 14 weeks after treatment with anti-TNF. Data were stratified according to EULAR clinical response criteria (poor, moderate, or good), defined at 30 weeks.
###end p 36
###begin p 37
###xml 59 62 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 194 197 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 419 422 410 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 790 798 778 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 921 929 909 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1017 1023 999 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1035 1038 1014 1017 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1328 1334 1304 1310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1347 1350 1320 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1440 1443 1410 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1489 1495 1456 1462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1573 1574 1528 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1583 1584 1538 1539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1594 1602 1549 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1776 1784 1731 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1787 1789 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1787 1789 1742 1744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B29">29</xref></sup>
###xml 1844 1850 1796 1802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1887 1895 1839 1847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1940 1943 1889 1892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 2037 2045 1986 1994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2072 2075 2018 2021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 2275 2278 2218 2221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
We reasoned that accumulation and persistence of PB TCRzetadim effector T cells in anti-TNF responders might explain why disease flares occur on withdrawing anti-TNF therapy, after which TCRzetadim T cells would migrate back to the synovial joint compartment and reinitiate a local inflammatory response. Ethics precluded further investigation in patients, and so we opted to study transendothelial migration of TCRzetadim T-cell subsets in vitro. Preliminary experiments demonstrated that by 24 hours about 20% to 25% of PBLs from healthy donors migrate across TNF-stimulated endothelial monolayers cultured in the Transwell. Flow cytometric analysis demonstrated that cells migrating to the lower chamber expressed lower levels TCRzeta. This was true for both T-cell and NK cell subsets (Figure 6A), and the expression profiles for upper and lower chambers were quite comparable to those we had observed for PB and SF (Figure 5A). Transmigration did not perturb TCRzeta expression because the proportions of TCRzetabright and TCRzetadim T cells were similar to those in PB cultured for the same period in the absence of endothelial cells or Transwell, nor was it dependent on proliferation because CFSE fluorescence of migrating and nonmigrating T cells was comparable (data not shown). Even though there are many more TCRzetabright than TCRzetadim T cells in the population added to the upper chamber, a much higher proportion of TCRzetadim cells migrated when compared to their TCRzetabright counterparts (approximately70% versus 30%), differences more striking for CD4+ than CD8+ subsets (Figure 6B). Migration of PBLs could be further enhanced by the addition of CXCL-10, CCL5, or CXCL-12 to the lower chamber, chemokines known to be up-regulated in RA synovial joints (Figure 6C).29 Subset analysis revealed enhanced migration of TCRzetabright T cells in the presence of CXCL-12 (Figure 6D), whereas the migratory profiles of TCRzetadim cells were substantially higher and barely augmented in the presence of exogenous chemokine (Figure 6D). Indeed, for the TCRzetadim subset transmigration in response to CXCL-12 was reduced when compared to cells migrating in the absence of exogenous chemokine. Taken together, these results suggest that antigen-experienced TCRzetadim T cells have likely acquired in vivo the propensity to migrate in part through expression of chemokines and their cognate receptors at the cell surface.
###end p 37
###begin p 38
###xml 7 10 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 0 63 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCR&#950;<sup>dim</sup> T cells exhibit enhanced migratory capacity in vitro</bold>
###xml 95 96 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 704 710 688 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 722 725 703 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 914 915 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 926 927 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 939 940 920 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1076 1082 1054 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1094 1097 1069 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1218 1219 1193 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1378 1379 1353 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
TCRzetadim T cells exhibit enhanced migratory capacity in vitro. (A) Healthy donor PBLs (5 x 106) were applied to the gelatin-coated Transwell containing a monolayer of TNF-alpha-stimulated HUVECs and cells in upper and lower chambers harvested at 24 hours prior to staining for expression of CD3ϵ and TCRzeta and analysis by flow cytometry. Representative dot plots are shown. (B) Subset analysis of migrating cells. After 24 hours cells were harvested and stained for TCRzeta and CD3, CD4, or CD8, as in panel A. Data are expressed as the percentage of cells migrating relative to the total number of each cell subset added to the Transwell. The significance of differences between migration of TCRzetabright and TCRzetadim cells is shown. (C) The chemokines CXCL10, CCL5, or CXCL12 were added to each lower chamber of the Transwell at 50 ng/mL and the total number of PBLs migrating determined after 24 hours; *P < .013; **P = .063; ***P < .004 compared to cells migrating in the absence of exogenous chemokine. (D) The effects of each chemokine on the migration of TCRzetabright and TCRzetadim cells were determined by flow cytometry, as described. Differences in migration between subsets was highly significant (P < .002), with the exception of migration in response to CXCL12. Within subset differences between "medium" and CXCL12-stimulated cells were also significant (P < .023).
###end p 38
###begin p 39
###xml 33 36 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 371 372 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 379 382 373 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 442 443 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 450 451 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 488 489 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 497 498 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 505 508 493 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 623 631 611 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
Finally, we asked whether TCRzetadim cells accumulating in PB retain the capacity to migrate despite anti-TNF therapy. To this end, the migratory competence of PB cells obtained from RA patients with active disease at baseline was compared with cells acquired after 14 weeks of anti-TNF treatment. Although the results demonstrated a trend toward reduced migration of CD8+TCRzetadim T cells and a significant reduction in migration of the CD3-TCRzeta+ NK cell subsets, the capacity of CD3+ and CD4+TCRzetadim T-cell subsets to migrate across activated endothelium in vitro was not influenced by anti-TNF treatment in vivo (Figure 7). We believe that these results provide a rational explanation for disease flares associated with treatment withdrawal and have implications for both the design and monitoring of therapeutic regimens aimed at prolonged periods of biologic drug-free remission.
###end p 39
###begin p 40
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 14 17 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 0 100 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PB CD4<sup>+</sup>TCR&#950;<sup>dim</sup> T cells retain the capacity to migrate in vitro despite anti-TNF treatment in vivo</bold>
###xml 414 415 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 422 425 416 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 442 443 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 450 453 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 461 462 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 469 472 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 497 498 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 505 506 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 535 536 520 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 543 544 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 560 561 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 572 573 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
PB CD4+TCRzetadim T cells retain the capacity to migrate in vitro despite anti-TNF treatment in vivo. PBLs acquired from patients with RA at baseline and 14 weeks after treatment with anti-TNF were analyzed for their capacity to migrate in vitro using the transendothelial migration assay. Migrating cell subsets were determined by flow cytometry. Data are expressed as percent cells migrating for (A) PBLs and CD3+TCRzetadim T cells, (B) CD4+TCRzetadim and CD8+TCRzetadim T cells, and (C) the CD3-TCRzeta+ NK and the nonlymphocyte CD3-TCRzeta- cell subsets; *P = .066; **P < .047.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 401 404 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 729 732 717 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 948 951 933 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1001 1007 983 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 1468 1470 1444 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1471 1473 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1473 1473 1449 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31"/>
###xml 1473 1473 1449 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32"/>
###xml 1474 1476 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1468 1476 1444 1452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B30">30</xref><xref ref-type="bibr" rid="B31"/><xref ref-type="bibr" rid="B32"/>&#8211;<xref ref-type="bibr" rid="B33">33</xref></sup>
It seems likely that T cells expressing low levels of TCRzeta define polyclonal populations of antigen-experienced T cells in vivo based on their cell surface phenotype, tetramer staining, cytokine expression, proliferative responses, and migratory competence. Even though their accumulation in inflamed tissues appears consistent with this, we cannot yet account for the heterogeneity of this TCRzetadim population. This subset will include populations of T cells that have very recently engaged antigen, perhaps explaining their refractoriness to TCR restimulation, but also T cells in which loss of TCRzeta expression persists over time. Our data seem consistent with this because during an acute inflammatory response TCRzetadim cells are depleted from the PB compartment and enriched in inflamed tissue; TNF blockade reverses this. Furthermore, transendothelial migration experiments demonstrated an enhanced propensity for circulating TCRzetadim T cells to migrate when compared to their TCRzetabright counterparts, implying that migration is associated with, and perhaps even facilitated by, loss of TCRzeta expression in peripheral lymphoid organs. We suggest that on migration to tissues in vivo this subset would be exposed to an inflammatory milieu where hypoxia, reactive oxygen intermediates, depletion of essential nutrients, inflammatory cytokines, and activated cells of myeloid lineage each contribute to chronic down-regulation of TCRzeta expression.25,30-33 Therein, aberrant TCR signals and their functional sequelae may be perpetuated.
###end p 42
###begin p 43
###xml 98 101 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 650 652 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 653 655 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 650 655 637 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref></sup>
###xml 772 774 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 772 774 752 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B36">36</xref></sup>
###xml 871 874 840 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 884 892 853 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1219 1221 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1219 1221 1188 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B37">37</xref></sup>
###xml 1277 1278 1246 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1282 1286 1251 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1291 1292 1260 1261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1297 1298 1266 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1568 1571 1534 1537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 1904 1906 1863 1865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 1904 1906 1863 1865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B38">38</xref></sup>
###xml 1940 1943 1896 1899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 858 863 <span type="species:ncbi:9606">human</span>
###xml 1174 1182 <span type="species:ncbi:9606">patients</span>
We still do not fully understand which extracellular cues sustain the effector function of TCRzetadim T cells and how these apparently dysfunctional cells contribute actively to pathogenic processes, besides the apparent imbalance of TCR-dependent arrest of cell motility and competing chemokinetic "go" signals promoting adhesion and migration. One possibility is that TCRzeta-deficient TCR/CD3 complexes are capable of transmitting signals to induce and sustain inflammatory cytokine gene expression through compensatory up-regulation of the FcϵRIgamma signaling subunit, as first described in intraepithelial lymphocytes of TCRzeta-deficient mice.34,35 Indeed, T cells from TCRzeta-deficient mice are fully competent to differentiate into IFN-gamma-producing Th1 cells,36 a finding consistent with the enrichment for IFN-gamma and TNF-alpha expression in human TCRzetadim T cells (Figure 3). On the other hand, the relative absence of IL-10-expressing T cells in the same population could point to an intrinsic requirement for intact TCR signaling to maintain immune homeostasis through the generation or function of regulatory T-cell subsets, as suggested in studies of patients with diabetes treated with anti-CD3.37 Appropriate antigen-dependent expansion of adaptive CD4+CD25highCD62L-Foxp3+ regulatory T cells from a pool of differentiating effector T cells might fail for the same reason. An alternative possibility is that the chronic phase of effector function is maintained independently of antigen stimulation, as suggested by experiments in which TCRzetadim T cells produce IFN-gamma following engagement of costimulatory pathways, while at the same time stimulating monocytes to produce inflammatory cytokines such as TNF through cell contact-dependent pathways. Moreover, attenuation of TCRzeta-dependent signaling will perturb pathways of antigen-dependent activation-induced cell death.38 It follows from this that TCRzetadim T cells would persist in tissues over extended periods of time, further amplifying effector pathways mediated through cell contact with infiltrating macrophages, B cells, and resident stromal cells. Although such sustained T-cell effector responses might usefully serve to sustain immunity to foreign pathogens, they are clearly harmful in autoimmunity.
###end p 43
###begin p 44
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 181 183 181 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B39">39</xref></sup>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B39">39</xref></sup>
###xml 519 520 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 554 557 551 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 988 990 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 991 993 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 993 993 982 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41"/>
###xml 994 996 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 988 996 977 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B40">40</xref><xref ref-type="bibr" rid="B41"/>&#8211;<xref ref-type="bibr" rid="B42">42</xref></sup>
###xml 1108 1111 1094 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dim</sup>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 976 980 <span type="species:ncbi:10090">mice</span>
A direct link between the loss of integrity of signaling from the TCR/CD3 complex and the generation of a repertoire of arthritogenic T cells has recently been reported in SKG mice.39 A spontaneous mutation in ZAP-70, which uncouples membrane proximal TCR signal transduction, impairs thymic selection leading to a peripheral repertoire of autoreactive T cells, which, among other tissues, targets synovial joints manifesting as a symmetrical and destructive polyarthritis.39 There are striking similarities between CD4+ T cells from SKG mice and TCRzetadim T cells, not least of which being their profound hyporesponsiveness to TCR engagement, skewed T-helper cell differentiation favoring expression of TNF-alpha, IFN-gamma, and (in our hands) IL-17, in combination with a robust capacity to activate monocytes. These T-cell-monocyte interactions likely play a major role in promoting the chronic, excessive cytokine drive characteristic of both autoimmune arthritis in SKG mice and RA.17,40-42 Given the strong predilection to migrate to inflammatory tissues coupled with their effector phenotype, TCRzetadim T cells should now be considered a valid cellular target for treating a wide range of chronic inflammatory diseases.
###end p 44
###begin p 45
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
###end p 45
###begin title 46
Acknowledgments
###end title 46
###begin p 47
This work was supported by grants from the Wellcome Trust, the Arthritis Research Campaign, and the British Heart Foundation.
###end p 47
###begin p 48
The authors gratefully acknowledge Eugenio Macchiarulo for help with the tetramer staining and Jane Douglas for collecting clinical data.
###end p 48
###begin title 49
Authorship
###end title 49
###begin p 50
Contribution: Z.Z., C.L.G., A.-C.V., A.F., S.O., P.I. and A.R. performed research; P.A., A.V., and C. McClinton collected data; C. Monaco, F.M.-B., F.D., T.J.V., and F.M.B analyzed data; and Z.Z., C.L.G., and A.P.C. designed the research, analyzed data, and wrote the paper.
###end p 50
###begin p 51
Conflict-of-interest disclosure: The authors declare no competing financial interests.
###end p 51
###begin p 52
Z.Z. and C.L.G. contributed equally to this study.
###end p 52
###begin p 53
###xml 190 216 190 216 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">andrew.cope@imperial.ac.uk</email>
Correspondence: Andrew P. Cope, Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1, Aspenlea Rd, Hammersmith, London W6 8LH, United Kingdom; e-mail: andrew.cope@imperial.ac.uk.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation.
###end article-title 55
###begin article-title 56
The T cell antigen receptor: insights into organelle biology.
###end article-title 56
###begin article-title 57
Membrane protein association by potential intramembrane charge pairs.
###end article-title 57
###begin article-title 58
The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways.
###end article-title 58
###begin article-title 59
Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon.
###end article-title 59
###begin article-title 60
Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins.
###end article-title 60
###begin article-title 61
Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor.
###end article-title 61
###begin article-title 62
Building a multichain receptor: synthesis, degradation, and assembly of the T-cell antigen receptor.
###end article-title 62
###begin article-title 63
Failure to synthesize the T cell CD3-zeta chain: structure and function of a partial T cell receptor complex.
###end article-title 63
###begin article-title 64
###xml 64 69 <span type="species:ncbi:9606">human</span>
Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells.
###end article-title 64
###begin article-title 65
###xml 49 54 <span type="species:ncbi:9606">human</span>
Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.
###end article-title 65
###begin article-title 66
Serial triggering of many T-cell receptors by a few peptide-MHC complexes.
###end article-title 66
###begin article-title 67
TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response.
###end article-title 67
###begin article-title 68
Studies of T-cell activation in chronic inflammation.
###end article-title 68
###begin article-title 69
Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function.
###end article-title 69
###begin article-title 70
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
###end article-title 70
###begin article-title 71
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
###end article-title 71
###begin article-title 72
Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?
###end article-title 72
###begin article-title 73
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Functional consequences of noncognate interactions between CD4+ memory T lymphocytes and the endothelium.
###end article-title 73
###begin article-title 74
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
###end article-title 74
###begin article-title 75
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.
###end article-title 75
###begin article-title 76
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.
###end article-title 76
###begin article-title 77
An epigenetic view of helper T cell differentiation.
###end article-title 77
###begin article-title 78
Signaling and transcription in T helper development.
###end article-title 78
###begin article-title 79
Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface.
###end article-title 79
###begin article-title 80
Antigen-independent activation of naive and memory resting T cells by a cytokine combination.
###end article-title 80
###begin article-title 81
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
###end article-title 81
###begin article-title 82
###xml 130 138 <span type="species:ncbi:9606">patients</span>
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.
###end article-title 82
###begin article-title 83
Chemokines and chemokine receptors in rheumatoid arthritis.
###end article-title 83
###begin article-title 84
Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis.
###end article-title 84
###begin article-title 85
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.
###end article-title 85
###begin article-title 86
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.
###end article-title 86
###begin article-title 87
TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs.
###end article-title 87
###begin article-title 88
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Abnormal T cell development in CD3-zeta-/- mutant mice and identification of a novel T cell population in the intestine.
###end article-title 88
###begin article-title 89
###xml 22 26 <span type="species:ncbi:10090">mice</span>
T cell development in mice lacking the CD3-zeta/eta gene.
###end article-title 89
###begin article-title 90
Polarized development of memory cell-like IFN-gamma-producing cells in the absence of TCR zeta-chain.
###end article-title 90
###begin article-title 91
###xml 14 19 <span type="species:ncbi:9606">human</span>
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
###end article-title 91
###begin article-title 92
Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis.
###end article-title 92
###begin article-title 93
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.
###end article-title 93
###begin article-title 94
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice.
###end article-title 94
###begin article-title 95
Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis.
###end article-title 95
###begin article-title 96
###xml 12 17 <span type="species:ncbi:9606">human</span>
The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction.
###end article-title 96

